While I share your frustration with IMU’s market sensitive announcements often being met with red, I think it’s important to acknowledge how significantly negative it would for be for IMU’s IP suite if CHECKVacc proved toxic at Phase 1, thus the inverse is also true. Positive progression of any of IMU’s lines of treatment though these milestones is significant and absolutely worthy of being highlighted as such.
All IMO
k
IMU Price at posting:
18.3¢ Sentiment: Buy Disclosure: Held
